JAZZ [NASD]
Jazz Pharmaceuticals plc
Index- P/E- EPS (ttm)-0.86 Insider Own1.00% Shs Outstand62.44M Perf Week0.11%
Market Cap9.70B Forward P/E8.76 EPS next Y17.98 Insider Trans-11.04% Shs Float61.09M Perf Month-0.84%
Income-51.90M PEG- EPS next Q4.66 Inst Own97.20% Short Float4.42% Perf Quarter3.47%
Sales3.48B P/S2.79 EPS this Y-230.80% Inst Trans1.03% Short Ratio5.26 Perf Half Y9.09%
Book/sh51.26 P/B3.07 EPS next Y3.29% ROA-0.40% Target Price201.89 Perf Year14.32%
Cash/sh12.53 P/C12.58 EPS next 5Y7.57% ROE-1.40% 52W Range117.64 - 169.98 Perf YTD23.70%
Dividend- P/FCF10.53 EPS past 5Y-23.40% ROI-0.50% 52W High-6.96% Beta0.69
Dividend %- Quick Ratio2.50 Sales past 5Y15.80% Gross Margin85.00% 52W Low34.44% ATR3.98
Employees3200 Current Ratio3.70 Sales Q/Q24.10% Oper. Margin7.20% RSI (14)54.58 Volatility2.22% 2.73%
OptionableYes Debt/Eq1.88 EPS Q/Q108.90% Profit Margin-1.50% Rel Volume1.04 Prev Close157.60
ShortableYes LT Debt/Eq1.87 EarningsAug 03 AMC Payout- Avg Volume513.06K Price158.15
Recom1.90 SMA201.32% SMA502.57% SMA2008.18% Volume207,178 Change0.35%
Jun-14-22Initiated UBS Buy $194
Apr-06-22Downgrade Goldman Buy → Neutral $202 → $196
Nov-19-21Resumed Goldman Buy $198
Oct-07-21Resumed Jefferies Buy $172
Oct-05-21Initiated Citigroup Buy $200
Sep-23-21Initiated Needham Buy $220
May-19-21Resumed JP Morgan Overweight $183 → $206
Apr-07-21Resumed RBC Capital Mkts Outperform $186
Feb-05-21Reiterated H.C. Wainwright Buy $195 → $207
Feb-03-21Upgrade Piper Sandler Neutral → Overweight $150 → $175
Jan-29-21Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-16-20Initiated UBS Buy $174
Nov-03-20Reiterated H.C. Wainwright Buy $185 → $195
Oct-09-20Reiterated H.C. Wainwright Buy $175 → $185
Sep-14-20Resumed JP Morgan Overweight $175
Sep-14-20Downgrade Goldman Neutral → Sell $128
Aug-06-20Upgrade Morgan Stanley Equal-Weight → Overweight $177
Jul-28-20Upgrade Wolfe Research Peer Perform → Outperform
Jul-23-20Upgrade H.C. Wainwright Neutral → Buy
Apr-06-20Initiated Jefferies Buy $149
Aug-18-22 07:30AM  
Aug-16-22 09:55AM  
Aug-09-22 11:40AM  
Aug-05-22 03:16PM  
12:20PM  
Aug-04-22 01:40PM  
01:22PM  
Aug-03-22 06:25PM  
04:05PM  
12:47PM  
12:44PM  
11:43AM  
Aug-02-22 10:15AM  
09:40AM  
Jul-28-22 10:02AM  
09:55AM  
09:14AM  
Jul-27-22 10:01AM  
Jul-21-22 11:40AM  
08:07AM  
Jul-20-22 04:15PM  
Jul-19-22 12:45PM  
Jul-18-22 11:49AM  
Jul-13-22 10:00AM  
09:40AM  
Jul-12-22 09:55AM  
Jul-11-22 02:20PM  
Jul-07-22 07:23AM  
Jul-05-22 11:40AM  
Jul-01-22 08:20AM  
Jun-29-22 03:22PM  
03:11PM  
09:26AM  
Jun-28-22 09:13AM  
07:30AM  
05:21AM  
Jun-23-22 08:40AM  
Jun-22-22 09:40AM  
Jun-19-22 05:58AM  
Jun-16-22 11:30AM  
Jun-07-22 07:30AM  
Jun-06-22 11:46AM  
Jun-03-22 11:32AM  
Jun-01-22 04:15PM  
07:45AM  
May-25-22 05:21AM  
May-20-22 09:40AM  
May-17-22 02:13PM  
May-12-22 11:57AM  
May-09-22 07:00AM  
May-05-22 12:04PM  
10:32AM  
May-04-22 06:05PM  
04:10PM  
04:05PM  
May-03-22 04:15PM  
Apr-29-22 12:10PM  
Apr-27-22 03:03PM  
Apr-22-22 09:29AM  
Apr-21-22 07:42AM  
Apr-20-22 04:15PM  
10:49AM  
08:50AM  
Apr-14-22 08:20AM  
Apr-08-22 02:29PM  
01:00PM  
Apr-07-22 10:15AM  
09:25AM  
08:34AM  
07:00AM  
Apr-06-22 08:35AM  
Apr-03-22 06:10AM  
Apr-02-22 01:32AM  
Mar-31-22 11:30AM  
Mar-30-22 01:29PM  
Mar-29-22 04:15PM  
10:48AM  
Mar-28-22 07:48AM  
06:00AM  
Mar-25-22 10:27AM  
03:00AM  
Mar-24-22 07:30AM  
Mar-22-22 08:30AM  
Mar-20-22 08:33AM  
Mar-08-22 04:35PM  
Mar-02-22 02:20PM  
09:40AM  
Mar-01-22 05:45PM  
04:05PM  
Feb-28-22 04:15PM  
10:20AM  
Feb-25-22 09:42AM  
Feb-15-22 04:15PM  
03:01PM  
Feb-11-22 09:30AM  
Feb-04-22 04:38PM  
Feb-03-22 02:38PM  
Feb-02-22 07:30AM  
Feb-01-22 12:10PM  
Jan-31-22 05:14AM  
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carr PatriciaSVP, Chief Accounting OfficerAug 15Option Exercise113.102,000226,2007,934Aug 17 04:41 PM
Carr PatriciaSVP, Chief Accounting OfficerAug 15Sale160.062,142342,8545,934Aug 17 04:41 PM
Pearce SamanthaSVP, Head of Europe & InternatAug 04Option Exercise109.4553158,11811,840Aug 08 04:33 PM
Pearce SamanthaSVP, Head of Europe & InternatAug 04Sale155.0053182,30511,309Aug 08 04:33 PM
COZADD BRUCE CChairman & CEOAug 01Option Exercise46.929,700455,087361,612Aug 03 04:58 PM
COZADD BRUCE CChairman & CEOAug 01Sale154.317,3011,126,645354,311Aug 03 04:58 PM
Pearce SamanthaSVP, Head of Europe & InternatJul 12Option Exercise109.4553258,22711,841Jul 14 06:15 PM
Pearce SamanthaSVP, Head of Europe & InternatJul 12Sale155.0053282,46011,309Jul 14 06:15 PM
COZADD BRUCE CChairman & CEOJul 05Option Exercise46.839,700454,251360,687Jul 07 05:11 PM
Tovey Christopher J.EVP, COO & Managing Director EJul 05Option Exercise0.024,0328119,872Jul 07 05:17 PM
COZADD BRUCE CChairman & CEOJul 05Sale157.288,7751,380,146351,912Jul 07 05:11 PM
Tovey Christopher J.EVP, COO & Managing Director EJul 05Sale160.005,209833,44014,663Jul 07 05:17 PM
Pearce SamanthaSVP, Head of Europe & InternatJun 27Option Exercise109.458,508931,20119,817Jun 29 05:55 PM
Pearce SamanthaSVP, Head of Europe & InternatJun 27Sale155.008,5081,318,74011,309Jun 29 05:55 PM
Pearce SamanthaSVP, Head of Europe & InternatJun 08Option Exercise109.455,835638,64119,796Jun 10 05:24 PM
Pearce SamanthaSVP, Head of Europe & InternatJun 08Sale155.008,4871,315,48511,309Jun 10 05:24 PM
Sablich KimEVP & GM, North AmericaJun 07Sale151.052,441368,71424,754Jun 08 04:56 PM
Patil Neena MChief Legal Officer (CLO)Jun 06Sale152.151,000152,15031,600Jun 08 05:00 PM
Sablich KimEVP & GM, North AmericaJun 06Sale152.151,388211,18427,195Jun 08 04:56 PM
Carr PatriciaSVP, Chief Accounting OfficerJun 02Sale150.2613119,6846,234Jun 03 03:07 PM
COZADD BRUCE CChairman & CEOJun 02Sale150.001,000150,000350,987Jun 03 03:04 PM
COZADD BRUCE CChairman & CEOJun 01Option Exercise46.839,700454,251358,349Jun 03 03:04 PM
COZADD BRUCE CChairman & CEOJun 01Sale146.876,362934,369351,987Jun 03 03:04 PM
Carr PatriciaSVP, Chief Accounting OfficerMay 11Sale147.51722106,5056,234May 11 05:29 PM
Carr PatriciaSVP, Chief Accounting OfficerMay 10Sale144.1827339,3616,956May 11 05:29 PM
Carr PatriciaSVP, Chief Accounting OfficerMay 09Sale148.941,067158,9237,229May 11 05:29 PM
ORiordan AnneDirectorMay 09Sale148.9546669,4119,245May 11 05:45 PM
Larkin FinbarSVP, Technical OperationsMay 09Sale148.941,747260,19319,462May 11 05:35 PM
Patil Neena MChief Legal OfficerMay 06Sale153.9229645,55932,677May 10 05:03 PM
COZADD BRUCE CChairman & CEOMay 02Option Exercise46.839,700454,251355,762May 04 06:21 PM
COZADD BRUCE CChairman & CEOMay 02Sale156.637,2601,137,142348,502May 04 06:21 PM
COZADD BRUCE CChairman & CEOApr 04Option Exercise46.839,700454,251356,834Apr 06 05:12 PM
COZADD BRUCE CChairman & CEOApr 04Sale158.3310,7721,705,505346,062Apr 06 05:12 PM
COZADD BRUCE CChairman & CEOMar 17Option Exercise59.131,28876,159347,134Mar 21 02:01 PM
COZADD BRUCE CChairman & CEOFeb 01Option Exercise46.839,700454,251332,160Feb 03 04:41 PM
COZADD BRUCE CChairman & CEOFeb 01Sale139.236,372887,168325,788Feb 03 04:41 PM
COZADD BRUCE CChairman & CEOJan 03Option Exercise46.839,700454,251328,251Jan 05 04:36 PM
COZADD BRUCE CChairman & CEOJan 03Sale127.855,791740,387322,460Jan 05 04:36 PM
Smith Mark DouglasDirectorDec 02Sale121.3041750,5824,419Dec 06 07:17 PM
Cook Jennifer E.DirectorDec 02Sale121.3041750,5824,419Dec 06 07:13 PM
COZADD BRUCE CChairman & CEODec 01Option Exercise46.839,700454,251325,299Dec 03 04:52 PM
COZADD BRUCE CChairman & CEODec 01Sale122.666,748827,726318,551Dec 03 04:52 PM
Larkin FinbarSVP, Technical OperationsNov 12Sale135.7919726,75116,468Nov 16 04:13 PM
Sablich KimEVP & GM, North AmericaNov 11Sale135.012,748371,00021,135Nov 15 07:30 PM
COZADD BRUCE CChairman & CEONov 01Option Exercise46.839,700454,251322,092Nov 03 04:43 PM
COZADD BRUCE CChairman & CEONov 01Sale134.756,556883,391315,536Nov 03 04:43 PM
COZADD BRUCE CChairman & CEOOct 04Option Exercise46.839,700454,251318,990Oct 06 04:58 PM
COZADD BRUCE CChairman & CEOOct 04Sale129.876,598856,903312,392Oct 06 04:58 PM
Larkin FinbarSVP, Technical OperationsSep 08Sale134.51638,47416,579Sep 10 04:01 PM
COZADD BRUCE CChairman & CEOSep 01Sale131.5850065,790309,290Sep 03 04:57 PM